First Trust NYSE Arca Biotechnology Index Fund (FBT)

	Printer Friendly Page
	Fact Sheet
	Summary Prospectus
	Monthly Performance Report

Fund Summary

Investment Objective/Strategy - The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index^SM.

There can be no assurance that the Fund's investment objectives will be achieved.

The NYSE Arca Biotechnology Index^SM is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
The index is rebalanced quarterly based upon closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent an approximately equal weight in the index.

Fund Overview

Ticker	FBT
Fund Type	Biotechnology
Investment Advisor	First Trust Advisors L.P.
Investor Servicing Agent	Bank of New York Mellon
CUSIP	33733E203
ISIN	US33733E2037
Intraday NAV	FBTIV
Fiscal Year-End	12/31
Exchange	NYSE Arca
Inception	6/19/2006
Inception Price	$20.00
Inception NAV	$20.00
Rebalance Frequency	Quarterly
Gross Expense Ratio*	0.56%
Net Expense Ratio*	0.56%

* As of 5/1/2018

Expenses are capped contractually at 0.60% per year, at least until April 30, 2019.

Current Fund Data (as of 10/18/2018)

Closing NAV¹	$146.39
Closing Share Price²	$146.43
Bid/Ask Midpoint	$146.67
Bid/Ask Premium	0.19%
Total Net Assets	$3,301,162,102
Outstanding Shares	22,550,002
Daily Volume	108,515
Average 30-Day Daily Volume	483,112
Closing Share Price 52-Week High/Low	$159.14 / $119.22
Closing NAV 52-Week High/Low	$159.05 / $119.29
Number of Holdings	30

Fund Characteristics (as of 9/28/2018)⁴

Maximum Market Cap.	$134,173
Median Market Cap.	$9,662
Minimum Market Cap.	$2,359
Price/Book	6.14
Price/Sales	8.08

Top Holdings (as of 10/18/2018)

Holding	Percent
ACADIA Pharmaceuticals Inc.	4.63%
Bio-Techne Corporation	4.02%
IQIVA Holdings Inc.	3.96%
Neurocrine Biosciences, Inc.	3.80%
Regeneron Pharmaceuticals, Inc.	3.69%
Amgen Inc.	3.65%
Intercept Pharmaceuticals, Inc.	3.63%
Seattle Genetics, Inc.	3.60%
Illumina, Inc.	3.54%
BioMarin Pharmaceutical Inc.	3.49%

Holdings are subject to change.

NAV History (Since Inception)

Past performance is not indicative of future results.

Overall Morningstar Rating^TM (as of 9/30/2018)³

Among 129 funds in the Health category. This fund was rated 3 stars/129 funds (3 years), 3 stars/120 funds (5 years), 4 stars/97 funds (10 years).

Bid/Ask Midpoint vs. NAV (as of 9/30/2018)

Number of Days Bid/Ask Midpoint Above NAV

Quarter Ended	0-49 Basis Points	50-99 Basis Points	100-199 Basis Points	>=200 Basis Points
9/30/2018	34	0	0	1
6/30/2018	35	0	0	0
3/31/2018	53	0	0	0
12/31/2017	41	0	0	0

Number of Days Bid/Ask Midpoint Below NAV

Quarter Ended	0-49 Basis Points	50-99 Basis Points	100-199 Basis Points	>=200 Basis Points
9/30/2018	28	0	0	0
6/30/2018	29	0	0	0
3/31/2018	8	0	0	0
12/31/2017	22	0	0	0

The price used to calculate market return is determined by using the midpoint between the highest bid and the lowest offer on the stock exchange, on which shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated.

Month End Performance (as of 9/28/2018)

	3 Mos	YTD	1 Year	3 Year	5 Year	10 Year	Since Fund Inception⁵
Fund Performance *
Net Asset Value (NAV)	13.15%	27.27%	27.79%	16.03%	19.65%	20.83%	18.49%
After Tax Held	13.15%	27.27%	27.79%	16.03%	19.63%	20.82%	18.44%
After Tax Sold	7.79%	16.15%	16.45%	12.62%	16.06%	18.13%	16.21%
Market Price	13.18%	27.31%	27.85%	16.08%	19.63%	20.73%	18.49%

Index Performance **
NYSE Arca Biotechnology Index^SM	13.30%	27.71%	28.39%	16.62%	20.16%	21.45%	19.12%
NASDAQ Biotechnology Index	11.20%	14.69%	10.34%	7.05%	12.29%	16.80%	14.90%
S&P Composite 1500 Health Care Index	14.29%	18.03%	19.95%	15.58%	15.89%	14.66%	12.36%
S&P 500 Index	7.71%	10.56%	17.91%	17.31%	13.95%	11.97%	9.49%

Quarter End Performance (as of 9/28/2018)

	3 Mos	YTD	1 Year	3 Year	5 Year	10 Year	Since Fund Inception⁵
Fund Performance *
Net Asset Value (NAV)	13.15%	27.27%	27.79%	16.03%	19.65%	20.83%	18.49%
After Tax Held	13.15%	27.27%	27.79%	16.03%	19.63%	20.82%	18.44%
After Tax Sold	7.79%	16.15%	16.45%	12.62%	16.06%	18.13%	16.21%
Market Price	13.18%	27.31%	27.85%	16.08%	19.63%	20.73%	18.49%

Index Performance **
NYSE Arca Biotechnology Index^SM	13.30%	27.71%	28.39%	16.62%	20.16%	21.45%	19.12%
NASDAQ Biotechnology Index	11.20%	14.69%	10.34%	7.05%	12.29%	16.80%	14.90%
S&P Composite 1500 Health Care Index	14.29%	18.03%	19.95%	15.58%	15.89%	14.66%	12.36%
S&P 500 Index	7.71%	10.56%	17.91%	17.31%	13.95%	11.97%	9.49%

3-Year Statistics (as of 9/28/2018)

	Standard Deviation	Alpha	Beta	Sharpe Ratio	Correlation
FBT	23.98%	-9.16	1.68	0.72	0.65
NASDAQ Biotechnology Index	21.64%	-16.16	1.57	0.39	0.67
S&P Composite 1500 Health Care Index	11.70%	-1.62	1.02	1.24	0.81
S&P 500 Index	9.18%	---	1.00	1.71	1.00

Standard Deviation is a measure of price variability (risk). Alpha is an indication of how much an investment outperforms or underperforms on a risk-adjusted basis relative to its benchmark.Beta is a measure of price variability relative to the market. Sharpe Ratio is a measure of excess reward per unit of volatility. Correlation is a measure of the similarity of performance.

*Performance data quoted represents past performance. Past performance is not a guarantee of future results and current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and shares when sold or redeemed, may be worth more or less than their original cost.

After Tax Held returns represent return after taxes on distributions. Assumes shares have not been sold. After Tax Sold returns represent the return after taxes on distributions and the sale of fund shares. Returns do not represent the returns you would receive if you traded shares at other times. Market Price returns are based on the midpoint of the bid/ask spread on the stock exchange on which shares of the fund are listed for trading as of the time that the fund’s NAV is calculated. Returns are average annualized total returns, except those for periods of less than one year, which are cumulative. The fund's performance reflects fee waivers and expense reimbursements, absent which performance would have been lower.

After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor’s tax situation and may differ from those shown. The after-tax returns shown are not relevant to investors who hold their fund shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts.

**Performance information for the NYSE Arca Biotechnology Index^SM is for illustrative purposes only and does not represent actual fund performance.

Indexes do not charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown. Indexes are unmanaged and an investor cannot invest directly in an index.

NASDAQ Biotechnology Index - The Index includes securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria.

S&P Composite 1500 Health Care Index - The Index is a capitalization-weighted index of companies classified by GICS as health care within the S&P Composite 1500 Index.

S&P 500 Index - The Index is an unmanaged index of 500 stocks used to measure large-cap U.S. stock market performance.

Footnotes

¹	The NAV represents the fund's net assets (assets less liabilities) divided by the fund's outstanding shares .
²	Fund shares are purchased and sold on an exchange at their share price rather than net asset value (NAV), which may cause the shares to trade at a price greater than NAV (premium) or less than NAV (discount).
³	The Morningstar Rating^TM for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The Morningstar Rating does not include any adjustment for sales loads. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.
⁴	All market capitalization numbers are in USD$ Millions.
⁵	Inception Date is 6/19/2006

You should consider the fund's investment objectives, risks, and charges and expenses carefully before investing. You can download a prospectus or summary prospectus, or contact First Trust Portfolios L.P. at 1-800-621-1675 to request a prospectus or summary prospectus which contains this and other information about the fund. The prospectus or summary prospectus should be read carefully before investing.

ETF Characteristics

The fund lists and principally trades its shares on the NYSE Arca, Inc.

The fund's return may not match the return of the NYSE Arca Biotechnology Index^SM. Securities held by the fund will generally not be bought or sold in response to market fluctuations.

Investors buying or selling fund shares on the secondary market may incur customary brokerage commissions. Market prices may differ to some degree from the net asset value of the shares. Investors who sell fund shares may receive less than the share's net asset value. Shares may be sold throughout the day on the exchange through any brokerage account. However, unlike mutual funds, shares may only be redeemed directly from the fund by authorized participants, in very large creation/redemption units. If the fund's authorized participants are unable to proceed with creation/redemption orders and no other authorized participant is able to step forward to create or redeem, fund shares may trade at a discount to the fund's net asset value and possibly face delisting.

Risk Considerations

The fund's shares will change in value, and you could lose money by investing in the fund. One of the principal risks of investing in the fund is market risk. Market risk is the risk that a particular stock owned by the fund, fund shares or stocks in general may fall in value. There can be no assurance that the fund's investment objective will be achieved.

The fund may invest in small capitalization and mid capitalization companies. Such companies may experience greater price volatility than larger, more established companies.

Biotechnology and pharmaceutical companies are subject to changing government regulation which could have a negative effect on the price, profitability and availability of their products and services. Biotechnology and pharmaceutical companies face increasing competition from generic drugs, termination of their patent protection and technological advances which render their products or services obsolete. The research and development costs required to bring a drug to market are substantial and may include a lengthy review by the government, with no guarantee that the product will ever be brought to market or show a profit. Many of these companies may not offer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings.

First Trust Advisors L.P. is the adviser to the fund. First Trust Advisors L.P. is an affiliate of First Trust Portfolios L.P., the fund's distributor.

The NYSE Arca Biotechnology Index^SM is a trademark of the NYSE Group, Inc. or its affiliates ("NYSE") and is licensed for use by First Trust. The fund is not sponsored or endorsed by NYSE. NYSE makes no representation or warranty, express or implied, to the owners of the fund or any member of the public regarding the advisability of investing in the fund or the ability of the fund to track the performance of the various sectors represented in the stock market. NYSE has no obligation to take the needs of the owners of the fund into consideration in determining, composing or calculating the index. NYSE is not responsible for and has not participated in any determination or calculation made with respect to issuance or redemption of the fund.

©2018 Morningstar, Inc. All Rights Reserved. The Morningstar Rating^TM information contained herein: (1) is proprietary to Morningstar;(2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Not FDIC Insured • Not Bank Guaranteed • May Lose Value